S&P 500

5.431,60

-0,04%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

IMAB

I MAB (IMAB)

I MAB

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:IMAB

1 2 3 4 5 6 7 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
06/06/2024	08:14	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMAB	I MAB
06/06/2024	08:00	PR Newswire (US)	I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	NASDAQ:IMAB	I MAB
05/06/2024	08:00	PR Newswire (US)	I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	NASDAQ:IMAB	I MAB
30/05/2024	18:33	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:IMAB	I MAB
23/05/2024	18:05	GlobeNewswire Inc.	I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	NASDAQ:IMAB	I MAB
22/05/2024	08:00	PR Newswire (US)	I-Mab to Participate at the Jefferies Global Healthcare Conference	NASDAQ:IMAB	I MAB
30/04/2024	08:00	PR Newswire (US)	I-MAB Filed 2023 Annual Report on Form 20-F	NASDAQ:IMAB	I MAB
05/04/2024	08:00	PR Newswire (US)	I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:IMAB	I MAB
02/04/2024	17:01	PR Newswire (US)	I-Mab Announces Closing of the Divestiture of Business Operations in China	NASDAQ:IMAB	I MAB
14/03/2024	18:00	PR Newswire (US)	I-Mab Reports Full Year 2023 Financial Results and Business Update	NASDAQ:IMAB	I MAB
09/02/2024	18:01	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:IMAB	I MAB
08/02/2024	08:07	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMAB	I MAB
07/02/2024	08:00	PR Newswire (US)	I-Mab Signs Agreement to Divest its Assets and Business Operations in China	NASDAQ:IMAB	I MAB
06/02/2024	22:55	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:IMAB	I MAB
02/01/2024	19:08	Dow Jones News	ADRs Slump; FLJ Group Declines 21%	NASDAQ:IMAB	I MAB
01/12/2023	16:41	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:IMAB	I MAB
06/11/2023	10:00	PR Newswire (US)	I-Mab Announces Participation at Jefferies and Piper Conferences in November	NASDAQ:IMAB	I MAB
02/11/2023	09:00	PR Newswire (US)	Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)	NASDAQ:IMAB	I MAB
01/11/2023	09:00	PR Newswire (US)	I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023	NASDAQ:IMAB	I MAB
16/10/2023	09:00	PR Newswire (US)	I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023	NASDAQ:IMAB	I MAB
10/10/2023	09:00	PR Newswire (US)	I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503	NASDAQ:IMAB	I MAB
05/09/2023	09:00	PR Newswire (US)	I-Mab Announces Upcoming Participation at September Conferences	NASDAQ:IMAB	I MAB
17/08/2023	07:00	PR Newswire (US)	I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates	NASDAQ:IMAB	I MAB
08/08/2023	09:00	PR Newswire (US)	I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023	NASDAQ:IMAB	I MAB
05/07/2023	09:00	PR Newswire (US)	I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC	NASDAQ:IMAB	I MAB
22/06/2023	09:40	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:IMAB	I MAB
22/06/2023	09:00	PR Newswire (US)	I-Mab Announces the Appointment of Raj Kannan as CEO	NASDAQ:IMAB	I MAB
25/05/2023	18:01	PR Newswire (US)	I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023	NASDAQ:IMAB	I MAB
01/05/2023	09:00	PR Newswire (US)	I-MAB Filed 2022 Annual Report on Form 20-F	NASDAQ:IMAB	I MAB
01/05/2023	07:57	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:IMAB	I MAB